StockData
Viatris Inc logo

Viatris Inc (VTRS) stock

VTRSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 6/309% below fair value
$20.28−0.17 (-0.83%)

Close on Nov 18, 2026Market cap $23.29BP/E –Yield 2.37%

Viatris operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Viatris's operating income for the twelve months ending Jun 30, 2026 was -$87.30M. For fiscal 2025 it was -$2.66B, down 26467.3% from the year before. The highest annual figure on record is $1.61B in fiscal 2022.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$2.66B-26467.3%
FY2024Dec 31, 2024$10.10M-98.7%
FY2023Dec 31, 2023$766.20M-52.6%
FY2022Dec 31, 2022$1.61B–
FY2021Dec 31, 2021-$34.00M–
FY2020Dec 31, 2020-$210.80M-129.5%
FY2019Dec 31, 2019$715.50M-21.0%
FY2018Dec 31, 2018$905.60M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$6.30M-97.3%
Q1 FY2026Mar 31, 2026-$79.70M–
Q4 FY2025Dec 31, 2025-$192.70M–
Q3 FY2025Sep 30, 2025$178.80M-20.8%
Q2 FY2025Jun 30, 2025$233.00M–
Q1 FY2025Mar 31, 2025-$2.88B-1513.5%
Q4 FY2024Dec 31, 2024-$179.80M–
Q3 FY2024Sep 30, 2024$225.90M-50.0%
Q2 FY2024Jun 30, 2024-$239.90M-165.0%
Q1 FY2024Mar 31, 2024$203.90M-49.0%
Q4 FY2023Dec 31, 2023-$454.50M–
Q3 FY2023Sep 30, 2023$451.70M-19.4%
Q2 FY2023Jun 30, 2023$369.20M-32.7%
Q1 FY2023Mar 31, 2023$399.80M-43.5%
Q4 FY2022Dec 31, 2022-$201.30M–
Q3 FY2022Sep 30, 2022$560.10M+56.6%
Q2 FY2022Jun 30, 2022$548.70M–
Q1 FY2022Mar 31, 2022$707.40M–
Q4 FY2021Dec 31, 2021-$77.60M–
Q3 FY2021Sep 30, 2021$357.60M+1.8%
Q2 FY2021Jun 30, 2021-$47.80M-135.6%
Q1 FY2021Mar 31, 2021-$266.20M-244.1%
Q4 FY2020Dec 31, 2020-$881.10M–
Q3 FY2020Sep 30, 2020$351.40M–
Q2 FY2020Jun 30, 2020$134.20M–
Q1 FY2020Mar 31, 2020$184.70M–

More Viatris figures

See a number that looks wrong?